Abstract: Topical film forming compositions that are able to efficiently deliver active ingredients to keratinic surfaces in a timed release manner comprise a combination of acrylates copolymer and acrylates/VA copolymer, and a combination of propane-1,3 diol and glycerin. The sizes of the pores that develop in the dried film may be controlled or fine tuned.

Abstract: Provided is a method of preventing or treating gastroesophageal reflux disease, including administering to an subject in need thereof a composition including a plurality of fibers formed of ?-1-4-glucan, wherein the fibers have a diameter between 15 nm and 35 nm and a mean length of between 1.5 ?m and 3.5 ?m.

Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.

Abstract: A composition including a synergistic combination of a vitamin D3 or a derivative or precursor thereof and hyaluronic acid or derivate thereof encapsulated in a lipid based colloidal carrier system (preferably lipid based vesicles such as liposomes, niosomes, tranferosomes) and topical formulations thereof, as well as their use in the prevention and/or treatment of inflamed skin and mucous membrane, especially in the prevention and/or treatment of skin photodamage, in particular in the prevention and/or treatment of skin erythema (skin inflammation) and actinic keratosis, as well non melanoma skin cancer.

Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.

Abstract: Methods of use and compositions useful for moisturizing skin, conditioning skin, reducing lines and wrinkles, evening skin tone, lightening skin tone, increasing skin radiance, elasticity, skin barrier function, and/or skin firmness, reducing photodamage, reducing sagging skin, increasing anti-oxidant capacity in skin, MMP-1, MMP-3, MMP-9, pro-inflammatory cytokines (e.g., lipoxygenase, IL-6, 11-8, TNF-?, or VEGF), and/or elastase expression in skin, and/or increasing collagen expression in skin, elastin expression in skin, laminin expression in skin, and/or fibronectin expression in skin are disclosed herein. The composition includes a combination of one or more of Rosmarinus officianalis leaf extract, Caulerpa lentillifera extract, Morus alba fruit extract, and Porphyridium cruentum extract.

Abstract: The invention relates to biodegradable, biocompatible materials to promote regeneration of articular surfaces in the temporomandibular joint and, more particularly, to biomaterials and methods for facilitating fibrochondrocyte and chondrocyte growth in in-vitro and in-vivo environments. The materials include magnesium in solid form and polymer. The materials are effective to grow and regenerate fibrochondrocyte and chondrocyte cells, and restore bone cells.

Abstract: Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids.

Abstract: Methods of synthesizing chondroitin sulfate oligosaccharides are provided. Enzymatic schematic approaches to synthesizing structurally defined homogenous chondroitin sulfate oligosaccharides at high yields are provided. Synthetic chondroitin sulfate oligosaccharides ranging from 3-mers to 15-mers are provided.

Abstract: A preparation method of sodium hyaluronate with a full molecular weight distribution (MWD) is provided, including: step 1): spraying hydrogen peroxide on a sodium hyaluronate solid raw material, and conducting an ultraviolet (UV) irradiation treatment; step 2): dissolving a sodium hyaluronate degradation material in water, and adjusting a pH to higher than 7.0; step 3): subjecting a sodium hyaluronate alkaline solution to an ultrasonic treatment; step 4): preparing the sodium hyaluronate solid raw material into a sodium hyaluronate solution with a concentration of 0.1% to 1% (w/v), and thoroughly mixing the sodium hyaluronate solution in an addition proportion of 20% to 60% (v/v) with the sodium hyaluronate alkaline solution obtained after the ultrasonic treatment; and step 5): subjecting a resulting mixed solution to an adsorption treatment with diatomaceous earth and activated carbon, filtering for concentration, and drying a resulting concentrate to obtain the sodium hyaluronate with a full MWD.

Abstract: The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.

Abstract: A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s.

Abstract: A composition comprised of a plurality of levan oligomers, wherein at least 70% (w/w) of said plurality of levan oligomers are characterized by: (i) weight average molecular weights (MW) of 540 to 1000 g/mole, and (ii) a dispersity index (Ð) of less than 2 is disclosed herein. Uses of the levan composition, such as, as a feed additive, growth promoter and for improving the rejuvenation and healing of a human skin, are also disclosed.

Abstract: A hydrocolloid or aqueous solution comprising a poly alpha-1,3-glucan ether compound is disclosed having a viscosity of at least about 10 centipoise (cPs). The poly alpha-1,3-glucan ether compound in these compositions has a degree of substitution of about 0.05 to about 3.0. Also disclosed is a method for increasing the viscosity of a hydrocolloid or aqueous composition using a poly alpha-1,3-glucan ether compound.

Abstract: Wound-care composition and method of use. The composition comprises: a substrate; potassium alum; and urea. The potassium alum makes up 10.27 wt. % of the composition within a tolerance of +/- 50%; and the urea makes up 0.12 wt. % of the composition within a tolerance of +/- 50%. The method comprises applying the composition to a wound on a non-human animal.

Abstract: A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

Abstract: Herbal composition having an effect of reducing uric acid, which is made from the following herbal materials in specified portions by weight: 4-30 portions of Glabrous greenbrier rhizome, 2-15 portions of Chicory, 2-15 portions of Herba Plantaginis, 2-20 portions of Coix seed, and 2-10 portions of Kudzuvine Root. The composition may be used in combination with modern Western medicines to achieve optimal effects.

Abstract: The present disclosure generally relates to a fish feed or fish feed product including a binding agent that increases the particle size and stability of feces produced by fish that consume the fish feed or fish feed product. In general, the fish feed will include a binding against such as locust bean gum, cassia gum, xanthan gum, tara gum, or combinations thereof. Also provided are methods for increases fish feces stability and methods for eliminating suspended solids from a recirculating aquaculture system.

Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.

Abstract: The present invention relates to delivery devices adapted to mechanically dilate a pelvic anatomical canal, the delivery devices comprise a composition formulated as a gel comprising a beneficial or therapeutic agent, said delivery devices being capable of releasing the beneficial or therapeutic agent into the pelvic anatomical canal, specifically into the vaginal canal, and thereby treat vaginal conditions associated with vaginal narrowing, atrophy, or dryness.

Abstract: Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including a head mounted display to monitor one or more physiologic signals from the face or head of the subject is disclosed. A method for analyzing an ocular parameter of the subject to determine a sympathetic and a parasympathetic outflow thereto is disclosed.

Abstract: Provided are pharmaceutical compositions comprising an anion exchanger and a calcium salt; methods for inducing hemostasis at a site of bleeding by applying to the site of bleeding an effective amount of the compositions; and methods of preparation of the compositions.

Abstract: Antimicrobial polymer coating formulations are prepared that protect biological surfaces by treating, reducing, ameliorating, preventing or inhibiting pathogenic microorganism ingress to a human or animal host, reducing the potential for infection, particularly by necrotizing fasciitis originating microorganisms, through use of a polymer coating barrier containing antimicrobial agents that facilitates sustained release of biocidal agents active against such opportunistic microorganisms. Such formulations are effective for inhibiting microbial ingress pertaining to soft tissue and skin tears, abrasions, punctures and surgical wounds, and can be used as in water environments and as a skin protectant sunscreen and insect repellent.

Abstract: A cosmetic or dermocosmetic agent consisting of: galactomannans having molecular weights between 5 and 630 kDa, and crosslinked sulfated galactans having molecular weights between 7 and 3000 kDa. Methods of using the agent, including for skin tensing and rejuvenation.

Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.

Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycellium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.

Abstract: A preparation of a homogeneous polysaccharide from a Radix Puerariae aqueous extract is provided and the lipid-lowering activity of the polysaccharide is studied. It is proved through in vivo experiments that the homogeneous polysaccharide QL extracted from Radix Puerariae (a genuine medicinal material in Jiangxi Province) in the present disclosure has significant lipid-lowering activity, can significantly reduce a serum triglyceride content and a liver index, and can be used to develop a potential safe and effective lipid-lowering drug.

Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.

Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.

Abstract: A crosslinked polymeric network is disclosed. The crosslinked polymeric network comprises a reaction product of a first glycosaminoglycan, a second glycosaminoglycan, and a crosslinking agent, wherein the first glycosaminoglycan is different than the second glycosaminoglycan.

Abstract: The composition is a hydrogel which may be used to deliver therapeutics vaginally. The hydrogel may include a glycosaminoglycan. The glycosaminoglycan may include multiple thiol groups. The composition may also include a molecule that includes at least two thiol reactive sites. The composition may include a mucoadhesive agent as well as a therapeutic agent. The composition may deliver the therapeutic at a pH that is optimal for the vaginal environment, namely between about 3.5 and 5.0.

Abstract: Disclosed is a method for filling a root canal in a tooth. The method includes positioning a fiber in the root canal of the tooth, filling at least a portion of the root canal with an unset hydrogel composition, such that the unset hydrogel composition contacts at least a portion of the fiber, setting the hydrogel composition, thereby forming a set hydrogel, and removing the fiber from the set hydrogel, thereby leaving a channel in the set hydrogel. Methods and kits for repairing teeth are also described.

Abstract: A composition for the prevention and treatment of the oral cavity comprising hyaluronic acid and a Manuka-derived product is described. The composition of the invention stabilizes the hyaluronic acid protecting the same from the aggression of the hyaluronidase present in the oral cavity, in particular on the mucous membranes and on the gingival walls, thus increasing the overall efficacy and the therapeutic effect.

Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

Abstract: The invention comprises a method of industrial extraction of alginates from brown seaweeds of the family Sargassaceae of the order Fucales, as well as the product resulting from the method. The method includes the following stages: preparation of raw materials, crushing of the algae, pressure boiling of the algae, mixing the boiled algae with water, purification of the diluted algal mass, extraction of alginic acid, washing of the alginic acid, dehydration of the alginic acid, treatment of the alginic acid with sodium hydrogen carbonate, clarification of resultant sodium alginate solution, precipitation of sodium alginate gel, and drying of the sodium alginate gel.

Abstract: The invention provides a pharmaceutical composition of hyaluronic acid comprising repeating units of a disaccharide comprising glucuronic acid and N-acetylglucosamine, wherein a portion of the N-acetyl groups of the N-acetylglucosamine have been independently replaced with a group of the formula —N—C(O)—(C2-C4)-alkyl for treating hyperuicemia and gouty arthritis. Studies show that this composition is promising as an anti-gout therapeutic agent, which combines both anti-inflammatory actions as well as anti uracemic effects.

Abstract: Provided are a composition for inhibiting immune cell proliferation, including sialyllactose or a derivative thereof as an active ingredient, and a method of inhibiting immune cell proliferation, wherein the composition and the method may decrease expression of chemokines, decrease expression of pro-inflammatory cytokines, decrease production of inflammatory mediators, decrease expression of COX2, and decrease production of PEG2, and therefore, may be useful for the prevention or treatment of atopic dermatitis or arthritis.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solation or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: Described herein are methods for preventing a serious health consequence and/or tissue damage in a subject after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods involve administering to the subject a sulfated polysaccharide or the pharmaceutically acceptable salt or ester thereof after the subject has been exposed to ionizing radiation and/or chemotherapy. The methods described herein are most beneficial to cancer patients who suffer from mucositis after exposure to ionizing radiation.

Abstract: The present invention relates to a method for producing a flavour composition comprising providing a slurry of yeast cell walls and contacting the slurry of yeast cell walls with a glucanase and with an endoprotease, followed by separating a liquid fraction by solid/liquid separation to provide the liquid flavour composition.

Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).

Abstract: The present invention provides frozen confectionery (sherbet and frozen confectionery containing ice) containing a specific amount of isomaltodextrin that is easy to loosen without affecting a flavor.

Abstract: The invention relates to a cosmetic active ingredient comprising at least one Metschnikowia reukaufii extract, and the use of same for the cosmetic treatment of the skin, in particular for improving the radiance of the complexion by acting on the skin microbiota. The active ingredient is effective on mature skin. The invention also concerns compositions comprising the cosmetic active ingredient and a cosmetic method for treating the skin using these compositions.

Abstract: Disclosed are nutraceutical formulations, and methods of using these nutraceutical formulations for the mitigation of chronic malnutrition in an infant, wherein the infant is breast feeding from a lactating mother ingesting one or more of said nutraceutical formulations in accordance with a prescribed regimen.

Abstract: The invention relates to human milk oligosaccharides (HMO) and its use in treatment of autism spectrum disorder (ASD).

Abstract: The present disclosure provides soluble dietary fibers, food and beverage products including them, and methods for using them. In one aspect, the disclosure provides soluble dietary fiber having a fiber content of at least 97% as measured by AOAC 2001.03 and a DP1+DP2 content of no more than 3 wt % (e.g., no more than 2 wt %) on a dry solids basis. The soluble dietary fiber can be useful in variety of food and beverage applications including fermented foods and beverages like beer and sake.

Abstract: Disclosed are nutraceutical formulations, including extracts comprising the hydrophilic and lipophilic fractions of stabilized rice bran. Also disclosed are methods for using said nutraceutical formulations for the management or remediation of conditions related to type II diabetes in humans, including methods for decreasing HbA1c and fasting glucose blood concentrations, and for increasing serum fasting insulin levels.

Abstract: A method and a composition comprising human milk oligosaccharides for decreasing the production of detrimental proteolytic metabolites such as ammonia and branched chain fatty acids in the intestinal microbiota of humans, which is useful for the treatment of brain-gut disorders like autism, stress, anxiety, and depressive disorders, are disclosed. Methods of treatment of colon cancer and liver damage are also disclosed.